Validation of our platforms through excellent preclinical and clinical research
Information is being updated...
Solid immunomodulatory potential in peripheral blood mononuclear cell co-culture, indicating that it can regulate and modulate immune responses;
Platform Extensive in vitro characterization:
High yields and viability indicate it is a robust and reliable cell source;
Mesenchymal stem cell markers, and lack of HLA, suggest they are immunocompatible;
The lack of senescence indicates a young cell population with good proliferative capacity;
Karyotype is stable, indicating that the product does not exhibit chromosomal abnormalities.
Displayed marked improvement in gross changes of OA, such as cartilage osteophytes and subchondral bone exposure;
Platform has shown promising results in managing osteoarthritis and synovitis by promoting tissue repair, reducing inflammation, and improving joint function:
Osteoarthritis and Synovitis
Reduced the formation of fissures on the surface of the femoral condyle, indicating better preservation of articular cartilage;
Decreased the expression of inflammatory markers in the treated group synovium, indicating suppressed inflammation.
Reduced inflammatory cytokines and chemokines in bronchoalveolar lavage (BAL) fluid, indicating suppressed lung inflammation;
Platform has demonstrated potential in managing Acute Respiratory Distress Syndrome (ARDS) by reducing inflammation, promoting lung repair, and preventing fibrosis by suppressing the activation of pro-inflammatory cytokines:
Acute Respiratory Distress Syndrome (ARDS)
Reduced protein concentration in lavage fluid, suggesting a decrease in lung edema and permeability;
A reduced number of neutrophils, macrophages, eosinophils, and basophils in BAL fluid, indicating reduced inflammation, prevention of lung tissue damage, and improved oxygenation;
Reduced structural alveolar damage, consolidation, and inflammation, indicating a more favorable environment for repair and regeneration;
Downregulated inflammatory gene expression of lung tissue, indicating a reduction in lung damage and promotion of repair.
Improved the survival rate of animals;
Platform has shown positive effects in managing acute kidney injury by improving survival rate, serum and urine biochemistry, and preventing structural chronic kidney injury:
Acute Kidney Injury
Promoted and sustained normal diuresis, indicating that the kidneys can produce and excrete urine at a regular rate;
Improved biochemistry and electrolyte balance in urine and serum, indicating a preserved kidney function;
Reduced inflammation and oxidative stress in the kidney, indicating prevention of acute kidney injury;
Reduced structural damage preventing tubular dilatation, acute tubular necrosis, cast formation, loss of brush border, interstitial fibrosis, and tubular atrophy indicates a long-term protective effect on the kidney structure.
We are working hard to ensure that we provide you with the most comprehensive information as soon as possible.